News & Updates

Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.

Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.

Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.

Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).